tirzepatide and increased heart rate Does Increase Rate? Cardiovascular Effects Effects of tirzepatide on circulatory

Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist licensed for weight management in adults with obesity or overweight with comorbidities Common gastrointestinal side effects including nausea (affecting approximately 43% of patients) may indirectly reduce interest in sexual activity Significant weight loss can temporarily affect hormone levels, energy, and body image, though obesity itself is associated with higher rates of sexual dysfunction Weight loss may increase fertility

Did you know there are other benefits

In 2012, a group of scientists affiliated with the pharmaceutical company Novo Nordisk formulated semaglutide to address the needs of individuals with type 2 diabetes

For the entire group, the median vitamin B12 level before treatment was 328 (range, 244429) pmol/l, and 973 (range, 4761476) pmol/l after treatment